Biller J, Massey E W, Marler J R, Adams H P, Davis J N, Bruno A, Henriksen R A, Linhardt R J, Goldstein L B, Alberts M
Department of Neurology, University of Iowa, Iowa City 52242.
Neurology. 1989 Feb;39(2 Pt 1):262-5. doi: 10.1212/wnl.39.2.262.
An intravenous infusion of a low molecular weight heparinoid, with a reduced risk of hemorrhage, may be an alternative to heparin in the management of acute ischemic stroke. To evaluate this hypothesis, we studied the safety of the heparinoid, ORG 10172, in a dose-escalation study in 26 patients. The drug was administered as a loading bolus followed by a 7-day infusion in five rates with target anti-factor Xa levels from 0.2 to 1.0 U/ml. The drug was well tolerated; no major bleeding complications or thrombocytopenia occurred. There were no deaths or hemorrhagic transformation of cerebral infarctions. The results indicate that ORG 10172 at doses to achieve a level of 1.0 U/ml or less may be used safely in management of acute cerebral infarction.
在急性缺血性卒中的治疗中，一种出血风险较低的低分子量类肝素静脉输注可能是肝素的替代选择。为评估这一假设，我们在一项剂量递增研究中对26例患者研究了类肝素ORG 10172的安全性。药物先给予负荷推注，然后以五种速率进行为期7天的输注，目标抗Xa因子水平为0.2至1.0 U/ml。该药物耐受性良好；未发生重大出血并发症或血小板减少症。无死亡病例或脑梗死出血性转化。结果表明，剂量达到1.0 U/ml或更低水平的ORG 10172可安全用于急性脑梗死的治疗。
